Preparation of Montelukast Sodium and Graphene Nanomaterials for the Treatment of Asthma

This study focuses on the biomaterial effects of montelukast sodium and graphene oxide (GO) on the onset of asthma disease. First, the synthesis process was adopted, with 2-[3-(S)-[3-[2-(7-chloro-2-quinolinyl) vinyl] phenyl]-3-hydroxypropyl] benzyl ester as raw materials, to synthesize montelukast sodium, and then Hummers method was used to obtain graphene oxide (GO), and GO was reduced to obtain graphene (EG). After the preparation completed, the purity of montelukast sodium was tested by liquid chromatography (HPLC), and the structural analysis of graphene nanomaterials was performed by X-ray diffractometer and Raman spectroscopy. Firstly, 30 mice were selected to observe the effect of montelukast sodium on the number of Th17 and cytokine IL-17 levels in asthmatic mice, then 50 mice were selected to observe whether the graphene-based nanomaterials had little effect of oxidative stress index in rat lung tissue. In the experiment, the spectrum analysis and liquid chromatography analysis showed that the purity of the prepared montelukast sodium exceeded 99%. The prepared graphene nanomaterials showed a strong D peak at 1037 cm(-1) by Raman spectroscopy. The characteristic diffraction peak of 11.8 degrees graphene oxide (GO) (001) crystal surface in XRD proved the successful preparation of graphene oxide; the further development of airway inflammation in asthmatic mice by inhibiting Th17 cell differentiation and IL-17 gene expression could be inhibited by montelukast sodium. And, the increase of reactive oxygen species ( ROS) and malondialdehyde ( MDA) could be promoted by the application of GO+ ovalbumin in mice. The decrease of glutathione (GSH) also increased the rise of serum IgE and the expression of the inflammatory gene IL-4, that is, the allergic effects of asthma in mice could be aggravated by GO.